Literature DB >> 25195947

Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.

Hsien-Neng Huang1, Ming-Chieh Lin, Li-Hui Tseng, Ying-Cheng Chiang, Liang-In Lin, Yu-Feng Lin, Hsin-Ying Huang, Kuan-Ting Kuo.   

Abstract

AIMS: To understand the role of and differences in molecular alterations between endometrial and ovarian endometrioid adenocarcinomas. METHODS AND
RESULTS: We investigated the microsatellite status of 26 ovarian endometrioid adenocarcinomas (OVEMs), 42 endometrial endometrioid adenocarcinomas (EMCAs), and 19 concurrent (endometrial and ovarian) endometrioid adenocarcinomas. We evaluated the expression of the mismatch repair proteins, PTEN and ARID1A, and mutations of PTEN, KRAS, CTNNB1, and PIK3CA. High levels of microsatellite instability (MSI-H) were present in one of 26 OVEMs, 12 of 42 EMCAs, and four of 19 concurrent endometrioid adenocarcinomas. Only four of 19 concurrent endometrioid adenocarcinomas showed identical molecular alterations in their endometrial and ovarian components. Loss of ARID1A or loss of PTEN expression, and MSI-H, were more common in EMCAs than OVEMs (P = 0.044, P = 0.004, and P = 0.012, respectively). MSI-H in endometrial endometrioid adenocarcinomas was also related to loss of ARID1A expression (P < 0.001). In the cohort of MSI-H endometrioid adenocarcinomas involving the endometrium (n = 16), MSH6-deficient cases showed higher frequencies of CTNNB1 and PIK3CA mutations (P = 0.008 and P = 0.036, respectively), but lower frequencies of KRAS mutation (P = 0.011), than PMS2-deficient cases.
CONCLUSIONS: The different frequencies of molecular genetic alterations between endometrial endometrioid adenocarcinomas and ovarian endometrioid adenocarcinomas imply that distinct processes may be involved in their tumorigenesis or tumour progression.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  ARID1A; CTNNB1; PTEN; endometrial cancer; endometrioid adenocarcinoma; microsatellite instability; mismatch repair proteins; ovarian cancer

Mesh:

Substances:

Year:  2014        PMID: 25195947     DOI: 10.1111/his.12543

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  14 in total

1.  Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.

Authors:  Carlos Parra-Herran; Jordan Lerner-Ellis; Bin Xu; Sam Khalouei; Dina Bassiouny; Matthew Cesari; Nadia Ismiil; Sharon Nofech-Mozes
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.

Authors:  Shiho Asaka; Ting-Tai Yen; Tian-Li Wang; Ie-Ming Shih; Stephanie Gaillard
Journal:  Mod Pathol       Date:  2018-11-06       Impact factor: 7.842

3.  Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.

Authors:  Rachel N Grisham; Kathleen N Moore; Michael S Gordon; Wael Harb; Gwendolyn Cody; Darragh F Halpenny; Vicky Makker; Carol A Aghajanian
Journal:  Clin Cancer Res       Date:  2018-05-29       Impact factor: 12.531

Review 4.  The roles of pathology in targeted therapy of women with gynecologic cancers.

Authors:  Rajmohan Murali; Rachel N Grisham; Robert A Soslow
Journal:  Gynecol Oncol       Date:  2017-11-23       Impact factor: 5.482

Review 5.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Authors:  Valerie Lee; Adrian Murphy; Dung T Le; Luis A Diaz
Journal:  Oncologist       Date:  2016-07-13

6.  Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion.

Authors:  Harika Sabbineni; Abdulrahman Alwhaibi; Anna Goc; Fei Gao; Alanna Pruitt; Payaningal R Somanath
Journal:  Eur J Pharmacol       Date:  2015-07-03       Impact factor: 4.432

7.  Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.

Authors:  Stacey A Cohen; Emily H Turner; Mallory B Beightol; Angela Jacobson; Ted A Gooley; Stephen J Salipante; Sigurdis Haraldsdottir; Christina Smith; Sheena Scroggins; Jonathan F Tait; William M Grady; Edward H Lin; David E Cohn; Paul J Goodfellow; Mark W Arnold; Albert de la Chapelle; Rachel Pearlman; Heather Hampel; Colin C Pritchard
Journal:  Gastroenterology       Date:  2016-06-11       Impact factor: 22.682

8.  Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis.

Authors:  Alaa Salah Jumaah; Hawraa Sahib Al-Haddad; Mais Muhammed Salem; Katherine Ann McAllister; Akeel Abed Yasseen
Journal:  J Pathol Transl Med       Date:  2021-04-14

9.  Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis.

Authors:  Pengfei Kong; Ruiyan Wu; Yadong Lan; Wenzhuo He; Chenlu Yang; Chenxi Yin; Qiong Yang; Chang Jiang; Dazhi Xu; Liangping Xia
Journal:  J Cancer       Date:  2017-09-16       Impact factor: 4.207

10.  Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification.

Authors:  Charlie Gourley; C Simon Herrington; Robert L Hollis; Barbara Stanley; John P Thomson; Michael Churchman; Ian Croy; Tzyvia Rye; Clare Bartos; Fiona Nussey; Melanie Mackean; Alison M Meynert; Colin A Semple
Journal:  NPJ Precis Oncol       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.